Morgan Stanley Boosts Epizyme (NASDAQ:EPZM) Price Target to $28.00
Epizyme (NASDAQ:EPZM) had its target price raised by equities research analysts at Morgan Stanley from $26.00 to $28.00 in a research note issued on Friday, BenzingaRatingsTable reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price target points to a potential upside of 21.58% from the stock’s current price.
Several other equities research analysts have also issued reports on the company. Citigroup raised their price objective on Epizyme from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday. Leerink Swann lowered Epizyme from an “outperform” rating to a “market perform” rating in a research report on Friday. Zacks Investment Research lowered Epizyme from a “hold” rating to a “sell” rating and set a $11.00 target price for the company. in a research report on Monday, October 21st. HC Wainwright reaffirmed a “buy” rating on shares of Epizyme in a research report on Thursday, October 31st. Finally, ValuEngine lowered Epizyme from a “hold” rating to a “sell” rating in a research report on Thursday, November 7th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $26.14.
Shares of NASDAQ:EPZM traded down $3.69 during trading on Friday, hitting $23.03. The company had a trading volume of 1,732,195 shares, compared to its average volume of 1,233,114. The stock has a market cap of $2.32 billion, a price-to-earnings ratio of -14.30 and a beta of 2.68. Epizyme has a one year low of $8.84 and a one year high of $27.82. The company has a fifty day simple moving average of $22.25 and a two-hundred day simple moving average of $15.12. The company has a debt-to-equity ratio of 0.03, a current ratio of 10.90 and a quick ratio of 10.90.
Hedge funds and other institutional investors have recently modified their holdings of the business. Vigilant Capital Management LLC bought a new stake in Epizyme during the 4th quarter valued at $32,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Epizyme by 29.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,564 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 1,262 shares in the last quarter. United Services Automobile Association bought a new stake in Epizyme during the 2nd quarter valued at $134,000. Perigon Wealth Management LLC bought a new stake in Epizyme during the 4th quarter valued at $201,000. Finally, Man Group plc bought a new stake in Epizyme during the 2nd quarter valued at $222,000. 86.95% of the stock is owned by institutional investors and hedge funds.
Epizyme Company Profile
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Recommended Story: Beige Book
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.